IM Cannabis Reports First Quarter Financial Results

Rhea-AI Summary

IM Cannabis Corp. (NASDAQ: IMCC) reported strong Q1 2025 financial results, marking a significant turnaround with a net profit of $175K. The company achieved notable improvements including a 94% increase in gross profit to $3.5M, 4% revenue growth to $12.5M, and a 50% reduction in operating expenses. The company's Non-IFRS Adjusted EBITDA showed a 129% improvement, reaching a profit of $0.6M compared to a previous loss of $2.2M.

Key financial metrics include a significant operating ratio improvement to 26% (down from 77%), and increased cash position of $1.4M. The company also announced plans for a non-brokered private placement of secured debentures for up to C$2.5M. Despite positive operational results, the financial statements include a going concern note, indicating ongoing liquidity challenges.

Positive

• Achieved net profit of $175K, turning around from previous losses
• 94% increase in gross profit to $3.5M year-over-year
• 4% revenue growth to $12.5M compared to Q1 2024
• 56% reduction in operating expenses from $7.4M to $3.3M
• 129% improvement in Adjusted EBITDA to $0.6M profit
• 15% increase in total assets to $44.9M

Negative

• Going concern note in financial statements indicates continued liquidity risks
• 16% increase in total liabilities to $41.8M
• Need for additional financing through private placement of secured debentures
• Decreased revenue in Israel market segment

Insights

Financial Analyst

IMC's Q1 shows impressive turnaround with first net profit, 94% gross profit growth, and significant operational efficiency improvements.

The Q1 2025 results represent a significant inflection point for IM Cannabis, marking the company's transition to profitability after a period of restructuring. The $175,000 net profit compared to a $6 million loss in Q1 2024 demonstrates remarkable financial improvement. This turnaround is primarily driven by operational efficiencies rather than dramatic revenue growth, with revenues only increasing by a modest 4% year-over-year to $12.5 million.

The most compelling aspects of these results are the 94% increase in gross profit to $3.4 million and the 56% reduction in operating expenses to $3.3 million. This dramatic cost-cutting has transformed the company's operating ratio from 77% to just 26%, indicating substantially improved operational efficiency. The shift to positive Adjusted EBITDA of $0.6 million (a 129% improvement) further validates their strategic reset.

The geographical revenue shift is notable - accelerated growth in Germany ($6.6 million) completely offset decreased revenue in Israel ($6.1 million), suggesting a strategic pivot toward the higher-margin European market.

Despite these improvements, several risk factors remain. The company still includes a going concern note in its financial statements, and the planned $2.5 million convertible debenture offering appears designed to refinance existing debt maturing on May 26, 2025. Cash position remains tight at $1.4 million, while liabilities increased by 16% to $41.8 million, primarily in trade payables and other accounts payable, potentially indicating strained supplier relationships.

This quarterly performance shows tangible progress in the company's transformation, but sustaining profitability while managing the significant debt load will be crucial challenges in coming quarters.

IMC Delivers Net Profit and 87% Gross Margin Improvement in Q1, Reflecting Strategic and Operational Progress

TORONTO and GLIL YAM, Israel, May 15, 2025 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IMC") (NASDAQ: IMCC) (CSE: IMCC), an international medical cannabis company, announced its financial results today for the first quarter ended March 31, 2025. All amounts are reported in Canadian dollars and compared to the quarter ended March 31, 2024, unless otherwise stated.

IMC also announces the intention to complete a non-brokered private placement of secured debentures.

Q1 2025 Financial Highlights

• Net profit of $175K
  
  
• 94% Gross profit increase vs. Q1 2024 of $3.5M vs. $1.8M and 29% Gross profit increase vs. Q4 2024 of $2.7M
  
  
• 4% Revenue increase vs. Q1 2024 of $12.5M vs. $12.1M
  
  
• 50% decrease in operating expenses vs. Q1 2024 excluding the one-time Oranim revocation related losses of $3.3M vs. $6.6M and 56% decrease including Oranim
  
  
• 129% increase of Non-IFRS Adjusted EBITDA profit to $0.6M vs. loss of $2.2M 

 

Management Commentary

"Q1 2025 is a clear inflection point for IMC," said Oren Shuster, Chief Executive Officer of IMC. "Achieving net profitability and an 87% improvement in gross margin year-over-year demonstrates the strength of the strategic and operational groundwork we laid in 2024—and reinforces our trajectory toward sustained, profitable growth"

"IMC's Q1 2025 results mark a major turning point in our financial performance. We achieved net profitability, driven by a 94% increase in gross profit, a 56% reduction in operating expenses and a 4% increase in revenue year-over-year," said Uri Birenberg, Chief Financial Officer of IMC. "Our operating ratio improved significantly to 26%, down from 77% in Q1 2024, and our Non-IFRS Adjusted EBITDA grew to $0.6 million—up 129% from a $2.2 million loss a year ago. These results reflect the strength of our strategy and the discipline with which we are executing it."

Operational Highlights

The Company intends to complete a non-brokered private placement (the "Offering") of secured convertible debentures of the Company (each, a "Debenture") for aggregate proceeds of up to C$2,500,000. The Debentures will mature on the date that is 12 months from the date of issuance and will not incur interest except in the event of default. The Debentures are being issued to holders of debentures that mature on May 26, 2025. The principal of the Debenture may be converted into common shares in the Company at a conversion price to be determined at the time of issuance.

Q1 2025 Conference Call 

The Company will host a Zoom web conference call today at 9:00 a.m. ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration.

If you are unable to join us live, a recording of the call will be available on our website at https://investors.imcannabis.com/ within 24 hours after the call.

Q1 2025 Financial Results

• Net Profit in Q1 2025 was $0.2 million, compared to net loss of $6 million in Q1 2024.
  
  
• Revenues for the first quarter of 2025 were $12.5 million compared to $12.1 million in the first quarter of 2024, an increase of 4%. The increase is mainly due to accelerated growth in Germany of $6.6 million and offset by decreased revenue in Israel of $6.1 million.
  
  
• Gross profit for the first quarter of 2025 was $3.4 million, compared to $1.8 million in Q1 2024, an increase of 94%.
  
  
• Total operating expenses in Q1 2025 were $3.3 million compared to $7.4 million in Q1 2024, a decrease of 56%.
  
  
• G&A Expenses in Q1 2025 were $2 million, compared to $2.3 million in Q1 2024, a decrease of 14%.
  
  
• Selling and Marketing Expenses in Q1 2025 were $1.3 million, compared to $2.3 million in Q1 2024, a decrease of 44%.
  
  
• Basic and diluted Profit per Share in Q1 2025 was $0.09, compared to a loss of $2.52 per Share in Q1 2024.
  
  
• Non-IFRS Adjusted EBITDA Profit in Q1 2025 was $0.6 million, compared to an adjusted EBITDA loss of $2.2 million in Q1 2024, an increase of 129%.
  
  
• Cash and Cash Equivalents as of March 31, 2025, were $1.4 million compared to $0.9 million in December 31, 2024.
  
  
• Total assets as of March 31, 2025, were $44.9 million, compared to $39.2 million in December 31, 2024, an increase of 15%. The increase is mainly attributed to an increase of $2.9 million in trade receivables and an increase of $2.2 million in Inventory.
  
  
• Total Liabilities as of March 31, 2025, were $41.8 million, compared to $36 in December 31, 2024, an increase of 16%. The increase is mainly attributed to an increase of $4.9 million in trade payables, an increase of $3.7 million in other accounts payable and offset by a decrease of $2.4 million due to reduction in Credit from bank institutions and others and long term credit.

The Company's financial statements as of March 31, 2025 includes a note regarding the Company's ability to continue as a going concern. The Company's Q1 2025 financial results do not include any adjustments relating to the recoverability and classification of assets or liabilities that might be necessary should the Company be unable to continue as a going concern. For more information, please refer to the "Liquidity and Capital Resources" and "Risk Factors" sections in the Company's management's discussion and analysis for the quarter ended March 31, 2025.

Non-IFRS Measures

This press release makes reference to "Gross Margin" and "Adjusted EBITDA", which are financial measures that are not recognized measures under IFRS and do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. These measures are provided as complementary information to the Company's IFRS measures by providing further understanding of our results of operations from management's perspective. Accordingly, these measures should neither be considered in isolation nor as a substitute for analysis of our financial information reported under IFRS.

For an explanation of how management defines Gross Margin and Adjusted EBITDA, see the Company's management's discussion and analysis for the period ended March 31, 2024, available under the Company's SEDAR+ profile at www.sedarplus.ca on EDGAR at www.sec.gov/edgar.

We reconcile these non-IFRS financial measures to the most comparable IFRS measures as set out below.

About IM Cannabis Corp.

IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.

The IMC ecosystem operates in Israel through Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.

Disclaimer for Forward-Looking Statements

This press release contains forward-looking information or forward-looking statements under applicable Canadian and United States securities laws (collectively, "forward-looking statements"). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect", "likely" and "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements relating to: the impact of the Israel-Hamas war on the Company, including its operations and the medical cannabis industry in Israel; the timing and impact of the legalization of medicinal cannabis in Germany, including, the Company having it "all in house"; the Company being positioned to take advantage of the legalization; the Company's growth in 2025; the market growth for medicinal cannabis in Germany;  the stated benefits of the Company's EU-GMP processing facility and an EU-GDP logistics center; the Company to host a teleconference meeting as stated; and the Company's stated goals, scope, and nature of operations in Germany, Israel, and other jurisdictions the Company may operate.

Forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to: the Company's ability to focus and resources to achieve sustainable and profitable growth in its highest value markets; the Company's ability to mitigate the impact of the Israel-Hamas war on the Company; the Company's ability to take advantage of the legalization of medicinal cannabis in Germany; the Company's ability to host a teleconference meeting as stated; and the Company's ability to carry out its stated goals, scope, and nature of operations in Germany, Israel, and other jurisdictions the Company may operate.

The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the Company's ability to continue to meet the listing requirements of the Canadian Securities Exchange and the NASDAQ Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and its subsidiaries (collectively, the "Group") to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group's obligations; the Group's possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group's cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt; risks surrounding war, conflict and civil unrest in Eastern Europe and the Middle East, including the impact of the Israel-Hamas war on the Company, its operations and the medical cannabis industry in Israel; risks associated with the Company focusing on the Israel and Germany markets; the inability of the Company to achieve sustainable profitability and/or increase shareholder value; the inability of the Company to actively manage costs and/or improve margins; the inability of the company to grow and/or maintain sales; the inability of the Company to meet its goals and/or strategic plans; the inability of the Company to reduce costs and/or maintain revenues; the Company's inability to take advantage of the legalization of medicinal cannabis in Germany; and the Company's inability to host a teleconference meeting as stated.

Please see the other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual report dated March 31, 2025, which is available on the Company's issuer profile on SEDAR+ at www.sedarplus.ca and Edgar at www.sec.gov/edgar. Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward looking information is made. The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

Company Contact: 

Anna Taranko, Director Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
a.taranko@imcannabis.de

Oren Shuster, CEO
IM Cannabis Corp.
+972-77-3603504
mailto:info@imcannabis.com

 

 

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
Canadian Dollars in thousands
					March 31, 2025			December 31, 2024
		Note			(Unaudited)
ASSETS
CURRENT ASSETS:
Cash					$            1,389			$            863
Restricted cash deposit					64			64
Trade receivables					16,653			13,803
Other current assets					5,981			5,419
Inventory			3		5,433			3,215
					29,520			23,364
NON-CURRENT ASSETS:
Investments in affiliate					1,598			1,631
Property, plant and equipment, net					3,752			3,730
Intangible assets, net					3,012			3,333
Goodwill					6,540			6,679
Right-of-use assets, net					512			451
					15,414			15,824
Total assets					$          44,934			$          39,188
The accompanying notes are an integral part of the interim condensed consolidated financial statements.

 

 

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
Canadian Dollars in thousands
				March 31, 2025		December 31, 2024
		Note		(Unaudited)
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
Current maturities of operating lease liabilities				$           306		$               262
Trade payables				16,036		11,159
Other current liabilities				8,677		5,001
Credit from bank institutions and others				12,916		15,145
Convertible debentures				2,042		1,968
Derivative warrants liabilities and prefunded warrants		4		817		1,383
				40,794		34,918
NON-CURRENT LIABILITIES:
Operating lease liabilities				200		171
Credit from bank institutions and others				314		466
Deferred tax liabilities				453		487
				967		1,124
Total liabilities				41,761		36,042
EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:		5
Share capital and premium				265,000		265,000
Capital reserve from translation differences of foreign operations				(1,502)		(1,265)
Conversion feature related to convertible debentures				297		297
Capital reserve from share-based payment transactions				158		150
Accumulated deficit				(258,629)		(258,939)
Total equity attributable to equity holders of the Company				5,324		5,243
Non-controlling interests				(2,151)		(2,097)
Total equity				3,173		3,146
Total liabilities and equity				$        44,934		$          39,188
The accompanying notes are an integral part of the consolidated financial statements

 

 

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (UNAUDITED)
Canadian Dollars in thousands, except per share data
				Three months ended March 31,
		Note		2025		2024
Revenues				$     12,500		$     12,063
Cost of revenues				9,052		10,274
Gross profit before fair value adjustments				3,448		1,789
Fair value adjustments:
Realized fair value adjustments on inventory sold in the period				-		(10)
Total fair value adjustments				-		(10)
Gross profit				3,448		1,779
General and administrative expenses				2,009		2,332
Selling and marketing expenses				1,273		2,292
Share-based compensation				8		32
Other operating expenses		9		-		2,753
Total operating expenses				3,290		7,409
Operating income (loss)				158		(5,630)
Finance expense, net		4		(12)		(501)
income (loss) before income taxes				146		(6,131)
Income tax benefit				29		111
Net income (loss)				$        175		$     (6,020)
The accompanying notes are an integral part of the consolidated financial statements.

 

 

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (UNAUDITED)
Canadian Dollars in thousands, except per share data
									Three months ended March 31,
						Note			2025				2024 (*)
Other comprehensive income that will not be reclassified   to profit or loss in subsequent periods:
Total other comprehensive income that will not be   reclassified to profit or loss in subsequent periods									35				67
Exchange differences on translation to presentation   currency									-				1,330
Total other comprehensive income (loss) that will not be   reclassified to profit or loss in subsequent periods									35				1,397
Other comprehensive income that will be   reclassified to profit or loss in subsequent periods:
Adjustments arising from translating financial statements   of foreign operation									(191)				(35)
Total other comprehensive income (loss) that will be   reclassified to profit or loss in subsequent periods									(191)				(35)
Total other comprehensive income (loss)									(156)				1,362
Total comprehensive income (loss)									$              19				$       (4,658)
Net income (loss) attributable to:
Equity holders of the Company									275				(5,623)
Non-controlling interests									(100)				(397)
									$            175				$       (6,020)
Total comprehensive income (loss) attributable to:
Equity holders of the Company									73				(4,252)
Non-controlling interests									(54)				(406)
									$              19				$       (4,658)
Net income (loss) per share attributable to equity holders   of the Company:						7
Basic and diluted income (loss) per share (in CAD)									$           0.09				$      (2.52)
(*)   Loss per share includes the effect of Reverse Share Split (see also Note 5a below).   The accompanying notes are an integral part of the consolidated financial statements.

 

 

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (UNAUDITED)
Canadian Dollars in thousands
		Share capital and premium		Reserve from share-based payment transactions		Conversion option for convertible debt		Translation reserve		Accumulated deficit		Total		Non-controlling interests		Total equity
Balance as of January 1, 2025		$   265,000		$        150		$             297		$      (1,265)		$   (258,939)		$ 5,243		$         (2,097)		$3,146
Net income (Loss)		-		-		-		-		275		275		(100)		175
Total other comprehensive income (loss)		-		-		-		(237)		35		(202)		46		(156)
Total comprehensive loss		-		-		-		(237)		310		73		(54)		19
Share-based compensation		-		8				-		-		8		-		8
Balance as of March 31, 2025		$   265,000		$           158		$           297		$      (1,502)		$  (258,629)		$   5,324		$      (2,151)		$3,173

 

 

		Share Capital  and premium		Reserve from share-based payment transactions		Translation reserve		Accumulated deficit		Total		Non-controlling interests		Total equity
Balance as of January 1, 2024		$     253,882		$            9,637		$              95		$      (249,145)		$   14,469		$           (769)		$      13,700
Net loss		-		-		-		(5,623)		(5,623)		(397)		(6,020)
Total other comprehensive loss		-		-		1,304		67		1,371		(9)		1,362
Total comprehensive loss		-		-		1,304		(5,556)		(4,252)		(406)		(4,658)
Other comprehensive income Classification		-		-		-		(730)		(730)		-		(730)
Share-based compensation		-		32		-		-		32		-		32
Forfeited options		5		(5)		-		-		-		-		-
Balance as of March 31, 2024		$       253,887		$            9,664		$            1,399		$      (255,431)		$      9,519		$          (1,175)		$         8,344
The accompanying notes are an integral part of the interim condensed consolidated financial statements.

 

 

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
Canadian Dollars in thousands
		Three months ended March 31,
		2025		2024
Cash provided by operating activities:
Net income (loss)		$           175		$     (6,020)
Adjustments for non-cash items:
Fair value adjustment on sale of inventory		-		10
Fair value adjustment on Warrants, investments and accounts    receivable		(565)		100
Interest recorded in respect of the convertible debt		73		-
Depreciation of property, plant and equipment		46		147
Amortization of intangible assets		338		452
Depreciation of right-of-use assets		79		118
Impairment of PPE		-		2,753
Finance expenses, net		504		401
Deferred tax liability, net		(40)		(69)
Share-based payment		8		32
Discount expenses in respect of credit		36		-
		479		3,944
Changes in working capital:
Increase (decrease) in trade receivables		(3,245)		1,332
Increase (decrease) in other accounts receivable and advances to   suppliers		(1,405)		159
Increase (decrease) in inventories, net of fair value adjustments		(2,349)		2,159
Increase in trade payables		5,270		663
Increase (decrease) in other accounts payable and accrued expenses		5,544		(2,745)
		3,815		1,568
Taxes paid		(6)		(121)
Net cash provided (used) in operating activities		4,463		(629)
Cash flows from investing activities:
Purchase of property, plant and equipment		-		(2)
Net cash used in investing activities		$          -		$        (2)
The accompanying notes are an integral part of the interim condensed consolidated financial statements.

 

 

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
Canadian Dollars in thousands
			Three months ended March 31,
			2025		2024
Cash flow from financing activities:
Proceeds from issuance of share capital, net of issuance costs		-			176
Proceeds from issuance of warrants		-			(176)
Repayment of lease liability		(68)			(118)
Interest paid - lease liability		(10)			(15)
Repayment of bank loan and credit facilities		(594)			(2,856)
Cash paid for interest		(976)			(444)
Proceeds (repayments) from discounted checks		(1,224)			2,581
Net cash provided (used) by financing activities		(2,872)			(852)
Effect of foreign exchange on cash and cash equivalents		(1,065)			718
Increase (decrease) in cash and cash equivalents		526			(765)
Cash and cash equivalents at the beginning of the period		863			1,813
Cash and cash equivalents at end of the period		$     1,389			$      1,048
Supplemental disclosure of non-cash activities:
Right-of-use asset recognized with corresponding lease liability		$        159			$           40
The accompanying notes are an integral part of the interim condensed consolidated financial statements.

 

Logo: https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/im-cannabis-reports-first-quarter-financial-results-302456550.html

SOURCE IM Cannabis Corp.

FAQ

What were IMCC's Q1 2025 earnings results?

IMCC reported a net profit of $175K in Q1 2025, with revenues of $12.5M (up 4% YoY) and gross profit of $3.4M (up 94% YoY). The company also achieved an Adjusted EBITDA profit of $0.6M.

How much did IMCC reduce its operating expenses in Q1 2025?

IMCC reduced its operating expenses by 56%, from $7.4M in Q1 2024 to $3.3M in Q1 2025.

What is the size of IMCC's planned private placement offering?

IMCC plans to complete a non-brokered private placement of secured convertible debentures for aggregate proceeds of up to C$2.5 million.

What is IMCC's current cash position as of Q1 2025?

IMCC reported cash and cash equivalents of $1.4M as of March 31, 2025, compared to $0.9M in December 31, 2024.

How did IMCC's gross margin improve in Q1 2025?

IMCC's gross profit increased by 94% year-over-year, from $1.8M in Q1 2024 to $3.4M in Q1 2025, reflecting significant margin improvement.